KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Acadia Pharmaceuticals (ACAD) over the last 16 years, with Q3 2025 value amounting to $399.6 million.

  • Acadia Pharmaceuticals' Total Non-Current Liabilities rose 396.6% to $399.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $399.6 million, marking a year-over-year increase of 396.6%. This contributed to the annual value of $436.9 million for FY2024, which is 4464.53% up from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Total Non-Current Liabilities stood at $399.6 million for Q3 2025, which was up 396.6% from $374.6 million recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Total Non-Current Liabilities registered a high of $436.9 million during Q4 2024, and its lowest value of $145.9 million during Q3 2021.
  • Over the past 5 years, Acadia Pharmaceuticals' median Total Non-Current Liabilities value was $257.7 million (recorded in 2023), while the average stood at $268.4 million.
  • In the last 5 years, Acadia Pharmaceuticals' Total Non-Current Liabilities skyrocketed by 6938.4% in 2023 and then plummeted by 858.96% in 2025.
  • Quarter analysis of 5 years shows Acadia Pharmaceuticals' Total Non-Current Liabilities stood at $152.2 million in 2021, then rose by 17.17% to $178.3 million in 2022, then surged by 69.38% to $302.1 million in 2023, then soared by 44.65% to $436.9 million in 2024, then decreased by 8.54% to $399.6 million in 2025.
  • Its last three reported values are $399.6 million in Q3 2025, $374.6 million for Q2 2025, and $347.2 million during Q1 2025.